Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial
The potential first-in-class ADC failed to significantly improve overall survival compared with docetaxel in previously treated nonsquamous NSCLC.
Angus Liu
Jun 23, 2026 7:15am
A 5-month sprint: Inside Pfizer's $10B deal with Innovent
Jun 21, 2026 10:41pm
Fierce Pharma
Eli Lilly is the ‘clear winner’ from ADA, RBC analyst says
Jun 8, 2026 3:12pm
ADA: Pfizer pads case for berobenatide in obesity
Jun 6, 2026 9:29am
Fierce Pharma
At ASCO, China biotech industry cements its coming of age
Jun 3, 2026 8:50am
Foundation Medicine tallies FDA nod for latest blood test
Jun 2, 2026 10:45am
